Chimura T, Morisaki N, Funayama T
Department of Obstetrics & Gynecology, School of Medicine, Yamagata University.
Jpn J Antibiot. 1991 Jun;44(6):662-8.
We conducted clinical efficacy and safety tests of flomoxef (FMOX, 6315-S) in the perinatal infections and obtained the following results. 1. A total of 25 patients was treated: 16 patients with intrauterine infections, 2 patients with pelvioperitonitis, 4 patients with urinary tract infections and 3 patients with other infections. FMOX was injected at a daily dose of 2-4 g for 3-15 days (6-60 g for total dose) by intravenous drip infusion, intravenous injection or their combination. 2. The clinical efficacy rate was 96.0% of 25 patients: excellent in 4 cases (16.0%), good in 20 cases (80.0%) and poor in 1 case (4.0%). Bacteriological effects obtained were: eradicated in 14/16 cases (87.5%) replaced in 3 cases. 3. There were no subjective or objective side effects, nor were any abnormal laboratory test values attributable to the drug. From these findings, we consider that FMOX treatment appears to obtain good clinical and bacteriological responses and in safe in perinatal period infections.
我们对氟氧头孢（FMOX，6315 - S）用于围产期感染进行了临床疗效和安全性试验，结果如下。1. 共治疗25例患者：16例为宫内感染，2例为盆腔腹膜炎，4例为尿路感染，3例为其他感染。氟氧头孢通过静脉滴注、静脉注射或两者联合的方式给药，每日剂量为2 - 4g，疗程3 - 15天（总剂量6 - 60g）。2. 25例患者的临床有效率为96.0%：4例（16.0%）为优，20例（80.0%）为良，1例（4.0%）为差。细菌学疗效为：14/16例（87.5%）根除，3例替换。3. 未出现主观或客观的副作用，也没有任何可归因于该药物的实验室检查值异常。基于这些发现，我们认为氟氧头孢治疗在围产期感染中似乎能获得良好的临床和细菌学反应，且是安全的。
